The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
about
Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment.Biomarkers for glioma immunotherapy: the next generationUnderstanding glioma stem cells: rationale, clinical relevance and therapeutic strategiesModern brain tumor imagingMeasurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Post-treatment imaging changes in primary brain tumors.Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report.Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasmsGenetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.Bevacizumab is safe in acute relapses of neuromyelitis optica.Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Vascular Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI.Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.Passive immunotherapeutic strategies for the treatment of malignant gliomas.The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomasInhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.Glioma stem cell maintenance: the role of the microenvironment.Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Which drug or drug delivery system can change clinical practice for brain tumor therapy?The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.Bevacizumab for glioblastoma-a promising drug or not?Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature.Vascular permeability in the RG2 glioma model can be mediated by macropinocytosis and be independent of the opening of the tight junction.Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.Direct effect of bevacizumab on glioblastoma cell lines in vitro.Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.Vascular normalization in cerebral angiogenesis: friend or foe?Apparent transverse relaxation (R2∗) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma.Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
P2860
Q26801485-6DAE239E-D23C-41CC-B4CA-C06DDE65269AQ26825496-8A6D1351-7182-4E8F-AF3E-F7BFB7FF36CAQ26995698-913D9E05-A441-4DCF-A3CD-2085D78DD333Q27002344-8BCDA600-87C4-4CC9-83CB-7C438F35A8CBQ30653828-48BA54BD-682A-4EB1-A26B-490361EA75C0Q30665022-D65278C9-6D00-4AB7-9CE5-9116E14B98E6Q30708866-7951E5D2-CCD8-4E29-B8B9-85BC2C8863C1Q30835236-CE9B6784-D85C-4E03-8ABB-0EDA6B5B9163Q30934034-9346DB23-727F-46CD-9127-9F982F8FC4CEQ33684824-936FE922-DF9C-4100-B969-024A1EA73AB2Q34369465-89E51D38-2F2A-4529-B908-154E543E63F3Q34943946-7FBD8FEF-76C6-479B-B9EB-ADA6F30F2DFAQ36428702-65797899-952C-4CE7-B42A-9CA6DCE245F6Q36500372-E00961D6-E2C3-4027-AE84-B167986605EDQ36510648-4CE82D86-ACF4-48AA-B5AB-7DD1A8DAE1C6Q36544101-CB9E0C10-7E55-48EA-AA0F-7B44615EE83FQ37380167-9B808448-9836-4D86-9F24-5DA788F7E9D5Q37474359-36F299EC-DE33-409E-A459-67AB0655B3CAQ37591724-31E1F9F1-CD36-4DA8-8B05-F120CED79653Q37714783-5B5337B3-FEE2-4641-A0B1-DA89A9B95A77Q37733640-140F1C61-480D-493A-A283-83519F1DEE6EQ37747100-164413C9-F715-4D5D-BB2B-CDF19E91D4DAQ37914244-3F96A572-C229-45D0-A529-FE5E63E0F769Q37993124-457EA443-3F38-4798-9E8A-6F3C3C3D62FAQ38090394-EF65BC27-8116-4EB6-874D-F9A8B1B4B63BQ38093776-0C6BF0CC-CF62-4155-AFF7-9EFFDB410723Q38161401-6F0047D9-43F8-4015-B629-E43B17D77331Q38351134-202551BA-1B07-4320-85F8-50B968A7E70EQ38551868-6FCF6FF5-C252-44A0-B812-F1D790364444Q38764263-A4EB6072-3424-430A-A1ED-22C2CE3DE707Q38800593-40B26107-94F5-4EA0-BB46-FF578A6F4D8EQ38822001-15E4F06A-7CB8-4E5B-AF5C-45E73182B6C4Q38967004-472A2617-0D03-419D-96F4-4BCDFD41AB94Q39225820-C252BAE9-51B7-454D-9622-E5D41415F3D6Q39313983-62B3E0B8-373E-4E91-A96F-D5A4340A43ABQ41096029-A2F3429A-62B2-413B-A9DB-528641E0B5FDQ42414835-6384ECEC-9DE0-4124-81A1-9CF1B4D2C62DQ47385832-27CFF4ED-4D80-42B1-8387-63FD4284D171Q48308766-DBD3538D-5F06-4B5D-8875-B13AE8AD57A1Q48345799-4D0BF260-C389-4700-AA33-1DBD461D38E1
P2860
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@ast
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@en
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@nl
type
label
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@ast
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@en
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@nl
prefLabel
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@ast
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@en
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@nl
P2860
P1433
P1476
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
@en
P2093
Eric M Thompson
Eugene P Frenkel
P2860
P356
10.1212/WNL.0B013E318204A3AF
P407
P577
2011-01-01T00:00:00Z